

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>MPM BioVentures 2014, L.P.</u>  (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET  (Street) CAMBRIDGE MA 01242  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/28/2021	3. Issuer Name and Ticker or Trading Symbol <u>Entrada Therapeutics, Inc. [ TRDA ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(1)	(1)	Common Stock	3,816,760	0.00 <sup>(1)</sup>	I	See Footnote <sup>(2)(3)</sup>
Series B Preferred Stock	(1)	(1)	Common Stock	509,024	0.00 <sup>(1)</sup>	I	See Footnote <sup>(2)(4)</sup>

1. Name and Address of Reporting Person* <u>MPM BioVentures 2014, L.P.</u>  (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET  (Street) CAMBRIDGE MA 01242  (City) (State) (Zip)
---

1. Name and Address of Reporting Person* <u>EVNIN LUKE</u>  (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET  (Street) CAMBRIDGE MA 012421  (City) (State) (Zip)
--

1. Name and Address of Reporting Person*
--

GADICKE ANSBERT

(Last) (First) (Middle)

C/O MPM CAPITAL  
450 KENDALL STREET

(Street)

CAMBRIDGE MA 01242

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

MPM BioVentures 2014 (B), L.P.

(Last) (First) (Middle)

C/O MPM CAPITAL  
450 KENDALL STREET

(Street)

CAMBRIDGE MA 01242

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

MPM Asset Management Investors  
BV2014 LLC

(Last) (First) (Middle)

C/O MPM CAPITAL  
450 KENDALL STREET

(Street)

CAMBRIDGE MA 01242

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

MPM BioVentures 2014 LLC

(Last) (First) (Middle)

C/O MPM CAPITAL  
450 KENDALL STREET

(Street)

CAMBRIDGE MA 01242

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

MPM BioVentures 2014 GP LLC

(Last) (First) (Middle)

C/O MPM CAPITAL  
450 KENDALL STREET

(Street)

CAMBRIDGE MA 01242

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

MPM BIOVENTURES 2018 (B), L.P.

(Last)	(First)	(Middle)
C/O MPM CAPITAL		
450 KENDALL STREET		
<hr/>		
(Street)		
CAMBRIDGE	MA	01242
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person\*

MPM ASSET MANAGEMENT INVESTORS BV2018 LLC

---

(Last)	(First)	(Middle)
C/O MPM CAPITAL		
450 KENDALL STREET		
<hr/>		
(Street)		
CAMBRIDGE	MA	01242
<hr/>		
(City)	(State)	(Zip)

**Explanation of Responses:**

- Each share of Series A Preferred Stock and Series B Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1:7.235890014 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock and Series B Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Preferred Stock and Series B Preferred Stock have no expiration dates.
- Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
- The shares are held as follows: 1,733,129 by MPM BioVentures 2014, L.P. ("BV 2014"), 115,596 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 59,655 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,778,737 by MPM BioVentures 2018, L.P. ("BV 2018"), 94,538 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 35,105 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evin and Gadick are managing directors of BV 2014 LLC and BV 2018 LLC.
- The shares are held as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014 LLC, 237,222 by BV 2018, 12,608 by BV 2018(B) and 4,682 by AM BV2018 LLC.

**Remarks:**

See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.

<u>/s/ Ansbert Gadicke,</u> <u>managing director of</u> <u>MPM BioVentures 2014</u> <u>LLC, the managing</u> <u>member of MPM</u> <u>BioVentures 2014 GP</u> <u>LLC, the general partner</u> <u>of MPM BioVentures</u> <u>2014, L.P.</u>	<u>10/28/2021</u>
<u>/s/ Luke Evin</u>	<u>10/28/2021</u>
<u>/s/ Ansbert Gadicke</u>	<u>10/28/2021</u>
<u>/s/ Ansbert Gadicke,</u> <u>managing director of</u> <u>MPM BioVentures 2014</u> <u>LLC, the managing</u> <u>member of MPM</u> <u>BioVentures 2014 GP</u> <u>LLC, the general partner</u> <u>of MPM BioVentures 2014</u> <u>(B), L.P.</u>	<u>10/28/2021</u>
<u>/s/ Ansbert Gadicke,</u> <u>managing director of</u> <u>MPM BioVentures 2014</u> <u>LLC, the manager of</u> <u>MPM Asset Management</u> <u>Investors BV2014 LLC</u>	<u>10/28/2021</u>
<u>/s/ Ansbert Gadicke,</u> <u>managing director of</u> <u>MPM BioVentures 2014</u> <u>LLC</u>	<u>10/28/2021</u>
<u>/s/ Ansbert Gadicke,</u>	<u>10/28/2021</u>

[managing director of  
MPM BioVentures 2014  
LLC, the managing  
member of MPM  
BioVentures 2014 GP LLC](#)

[/s/ Ansbert Gadicke,  
managing director of  
MPM BioVentures 2018  
LLC, the managing  
member of MPM  
BioVentures 2018 GP  
LLC, the general partner  
of MPM BioVentures 2018  
\(B\), L.P.](#) 10/28/2021

[/s/ Ansbert Gadicke,  
managing director of  
MPM BioVentures 2018  
LLC, the manager of  
MPM Asset Management  
Investors BV2018 LLC](#) 10/28/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**